LATEST UPDATES » Special Issue 1, March 2020 – Coronavirus Outbreak       » Vol 24, No. 03, March 2020 – Modern-Day Nostradamus: Predicting the Peak of COVID-19 in China with Mathematical Modelling       » A remote-controlled smart platform for organ repair       » COVID-19 and its genetic relationship with other coronaviruses       » Shedding Light on COVID-19 Vaccine Development       » AI enables whole-slide imaging for diagnosis of nasal polyps       » East meets West: cancer therapy using acupuncture and electrochemistry      
Vol 24, No. 03, March 2020For e-subscribers (PDF)
Shedding Light on COVID-19 Vaccine Development

Scientists at the Hong Kong University of Science and Technology (HKUST) identified potential vaccine targets for SARS-CoV-2 coronavirus.

Early 2020 saw the emergence and spread of COVID-19 across 28 different countries. This viral disease has now been found to be caused by SARS-CoV-2 due to its similarities to SARS-CoV which caused the SARS (Severe Acute Respiratory Syndrome) outbreak in 2003. As of 26 February 2020, the number of confirmed cases worldwide has reached 81,109 with a total of 2,761 deaths.

Both SARS-CoV and SARS-CoV-2 belong to the same Betacoronavirus genus, considering genetic similarity, the research team from HKUST made use of it to experimentally determine immunological data to identify a set of B cell and T cell epitopes that match exactly to SARS-CoV-2.

These epitopes are biomarkers recognized by the immune system to trigger actions against the virus. Genetic sequences of the epitopes were found to be genetically stable across available SARS-CoV-2 sequences, making suitable immune targets and potentially offer protection against COVID-19.

The research team was led by data scientists Professor Matthew McKay, a Professor in the Departments of Electronic & Computer Engineering and Chemical & Biological Engineering and Dr. Ahmed Abdul Quadeer, a post-doctoral fellow in the Department of Electronic & Computer Engineering. Their findings were published on the journal Viruses in February 2020.

Prof. McKay highlighted that "Despite similarities between SARS-CoV and SARS-CoV-2, there is genetic variation between the two, and it is not obvious if epitopes that elicit an immune response against SARS-CoV will likely be effective against SARS-CoV-2. We found that only roughly 20 percent of the SARS-CoV epitopes map identically to SARS-CoV-2 and believe these are promising candidates."

"For the identified T cell epitopes, we also performed a population coverage analysis and determined a set of epitopes that is estimated to provide broad coverage globally as well as in China" said Dr. Quadeer. The estimated population coverage represents the percentage of individuals within the selected population that are likely to elicit an immune response to at least one epitope from the identified set.

Click here for the complete issue.

news Proteona leads international consortium to develop SARS-CoV-2 neutralizing antibody to help vulnerable immunocompromised individuals
news One more step towards true precision medicine
news Joining Forces to Elevate Asia's Healthcare Industry
news 4th Global Feed Summit draws Feed Producers, Technology Providers, Raw Materials Suppliers to Bangkok for Key Discussions

About Us
Available issues
Editorial Board
Letters to Editor
Contribute to APBN
Advertise with Us
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Deborah Seah
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
Copyright© 2020 World Scientific Publishing Co Pte Ltd  •  Privacy Policy